Cyto-immuno-therapy for Cancer: a pathway elicited by tumor-targeted, cytotoxic drug-packaged bacterially derived nanocells

Cargando...
Miniatura

Fecha

2020

Título de la revista

Publicado en

Cancer Cell, 1878-3686, Vol. 37, No. 03, 2020, p. 354-370

Publicado por

CellPress

Enlace a contenidos multimedia

ISSN de la revista

Título del volumen

Resumen

Descripción

Abstract

Immunotherapy has emerged as a powerful new chapter in the fight against cancer. However, it has yet to reach its full potential due in part to the complexity of the cancer immune response. We demonstrate that tumor-targeting EDV nanocells function as an immunotherapeutic by delivering a cytotoxin in conjunction with activation of the immune system. These nanocells polarize M1 macrophages and activate NK cells concurrently producing a Th1 cytokine response resulting in potent antitumor function. Dendritic cell maturation and antigen presentation follows, which generates tumor-specific CD8+ T cells, conferring prolonged tumor remission. The combination of cytotoxin delivery and activation of innate and adaptive antitumor immune responses results in a potent cyto-immunotherapeutic with potential in clinical oncology.

Palabras clave

Cáncer, Terapia combinada, Citoinmunoterapia, Inmunoterapia, Nanocélulas, Supercitotoxina, Objetivo del tumor

Keywords

PNU-159682, Cancer, Combined therapeutic, Cyto-immunotherapy, Immunotherapy, Nanocell, Supercytotoxin, Tumor targeting

Temáticas

Citación

Colecciones